These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7138614)

  • 21. Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
    Wirth A; Middelhoff G; Braeuning C; Schlierf G
    Atherosclerosis; 1982 Dec; 45(3):291-7. PubMed ID: 7159500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
    Fringes B; Riede UN; von Deimling O
    Atherosclerosis; 1982 Sep; 44(3):391-2. PubMed ID: 7150401
    [No Abstract]   [Full Text] [Related]  

  • 23. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H
    Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H; Klein HJ
    Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of bezafibrate and clofibrate on cholesterol ester metabolism in rabbit peritoneal macrophages stimulated with acetylated low density lipoproteins.
    Hudson K; Mojumder S; Day AJ
    Exp Mol Pathol; 1983 Feb; 38(1):77-81. PubMed ID: 6832340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
    Anderson P; Norbeck HE
    Eur J Clin Pharmacol; 1981; 21(3):209-14. PubMed ID: 7318880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
    Stratmann FW; Holler HD; Hofmann H
    Med Welt; 1981 Feb; 32(8):268-71. PubMed ID: 7207168
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapeutic effects of bezafibrate in hyperlipidemia].
    Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
    Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Neuman MP; Kurlat MI; Neuman J
    Curr Med Res Opin; 1983; 8(5):358-67. PubMed ID: 6839800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study.
    Noring L; Kjellin KG; Ledermann H
    J Int Med Res; 1981; 9(5):319-23. PubMed ID: 7297756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of bezofibrate and clofibrate on cholesterol accumulation, esterification and removal in cultured 3T3 fibroblasts.
    Hudson K; Day AJ
    Atherosclerosis; 1981; 40(1):53-63. PubMed ID: 7284052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
    Janka HU; Standl A; Holler HD; Mehnert H
    MMW Munch Med Wochenschr; 1982 May; 124(21):535-7. PubMed ID: 6810123
    [No Abstract]   [Full Text] [Related]  

  • 38. Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.
    Oster P; Schlierf G; Lang PD; Mordasini R; Vollmar J
    Pharmatherapeutica; 1985; 4(5):267-77. PubMed ID: 4070320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB; Peters JR
    Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.